Pancreatic cancer is considered as one of the most aggressive tumor types, representing over 45,750 mortality cases annually in the USA solely. The aggressive nature and late identification of pancreatic cancer, combined with the restrictions of existing chemotherapeutics, present the mandatory need for the advancement of novel treatment systems. Ongoing reports have shown an important role of microRNAs (miRNAs) in the initiation, migration, and metastasis of malignancies. Besides, abnormal transcriptional levels of miRNAs have regularly been related with etiopathogenesis of pancreatic malignancy, underlining the conceivable utilization of miRNAs in the management of pancreatic disease patients. In this review article, we give a concise outline of molecular pathways involved in etiopathogenesis of pancreatic cancer patients as well as miRNA implications in pancreatic cancer patients. Ensuing sections describe the involvement of miRNAs in the diagnosis, prognosis, and therapy of pancreatic cancer patients. The involvement of miRNAs in the chemoresistance of pancreatic cancers was also discussed. End area portrays the substance of survey with future headings.

胰腺癌被认为是最具侵袭性的肿瘤类型之一，仅在美国每年就有超过 45,750 例死亡病例。胰腺癌的侵袭性和晚期识别，再加上现有化疗药物的限制，迫切需要推进新的治疗系统。正在进行的报告显示了 microRNA (miRNA) 在恶性肿瘤的起始、迁移和转移中的重要作用。此外，miRNA 的异常转录水平经常与胰腺恶性肿瘤的发病机制相关，这强调了 miRNA 在胰腺疾病患者管理中的可想象性应用。在这篇评论文章中，我们简要概述了参与胰腺癌患者发病机制的分子途径以及胰腺癌患者中 miRNA 的意义。随后的部分描述了 miRNA 在胰腺癌患者的诊断、预后和治疗中的作用。还讨论了 miRNA 在胰腺癌的化学抗性中的作用。末端区域描绘了带有未来标题的调查内容。